doctor pbm glp-1 approval process Glucagon-like peptide-1 receptor: mechanisms and advances in therapy Does Anthem cover GLP-1 for

CRISPR: The Platform Patent Dispute and Its Commercial Consequences CRISPR-Cas9 gene editing technology is subject to one of the most intensely litigated platform patent disputes in history, between the Broad Institute (controlling IP developed in Zhang Fengs laboratory) and the University of California (controlling IP from Jennifer Doudna and Emmanuelle Charpentiers work)

Cardioprotective effects of glucagon-like peptide 1 receptor agonists in heart failure: myth or truth

Microbiota-derived acetate enhances host antiviral response via NLRP3

They revealed that the glucagon precursor gene encoded additional peptides beyond glucagon [6,7]